Ashley Paul
NPI: 1902250335
Total Payments
$33,507
2024 Payments
$390.70
Companies
11
Transactions
49
Medicare Patients
295
Medicare Billing
$37,009
Payment Breakdown by Category
Other$30,000 (89.5%)
Food & Beverage$2,371 (7.1%)
Travel$988.86 (3.0%)
Education$146.41 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Grant | $30,000 | 2 | 89.5% |
| Food and Beverage | $2,371 | 33 | 7.1% |
| Travel and Lodging | $988.86 | 12 | 3.0% |
| Education | $146.41 | 2 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic, Inc. | $21,289 | 17 | $0 (2021) |
| Boston Scientific Corporation | $10,000 | 1 | $0 (2022) |
| ACADIA Pharmaceuticals Inc | $864.10 | 12 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $529.82 | 9 | $0 (2024) |
| GENZYME CORPORATION | $324.12 | 4 | $0 (2020) |
| Adamas Pharmaceuticals, Inc. | $124.72 | 1 | $0 (2018) |
| Biogen, Inc. | $90.13 | 1 | $0 (2019) |
| EMD Serono, Inc. | $86.19 | 1 | $0 (2019) |
| Merz Pharmaceuticals, LLC | $79.56 | 1 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $63.69 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $390.70 | 6 | Neurocrine Biosciences, Inc. ($220.45) |
| 2023 | $935.55 | 14 | ACADIA Pharmaceuticals Inc ($626.18) |
| 2022 | $10,147 | 3 | Boston Scientific Corporation ($10,000) |
| 2021 | $21,289 | 17 | Medtronic, Inc. ($21,289) |
| 2020 | $94.26 | 1 | GENZYME CORPORATION ($94.26) |
| 2019 | $295.19 | 4 | Biogen, Inc. ($90.13) |
| 2018 | $224.72 | 2 | Adamas Pharmaceuticals, Inc. ($124.72) |
| 2017 | $130.21 | 2 | GENZYME CORPORATION ($66.52) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/05/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: Neuropsychiatry | ||||||
| 06/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: Neuropsychiatry | ||||||
| 05/09/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $59.93 | General |
| Category: Neuropsychiatry | ||||||
| 03/21/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $170.25 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/02/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Neuropsychiatry | ||||||
| 02/01/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $94.47 | General |
| Category: Neuropsychiatry | ||||||
| 12/01/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $25.14 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/22/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $125.67 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/22/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $125.67 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 08/04/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 08/03/2023 | Neurocrine BioSciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $94.23 | General |
| Category: Neuropsychiatry | ||||||
| 06/29/2023 | Neurocrine BioSciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $104.62 | General |
| Category: Neuropsychiatry | ||||||
| 04/13/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $3.62 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/13/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $3.62 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/11/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $113.85 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/11/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $113.85 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/31/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $8.42 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 02/16/2023 | Neurocrine BioSciences, Inc. | Ongentys (Drug), INGREZZA | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: Neuropsychiatry | ||||||
| 02/09/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $94.50 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 01/12/2023 | Neurocrine BioSciences, Inc. | Ongentys (Drug) | Food and Beverage | In-kind items and services | $86.94 | General |
| Category: Neuropsychiatry | ||||||
| 12/09/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $67.67 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/29/2022 | Boston Scientific Corporation | Vercise (Device) | Grant | Cash or cash equivalent | $10,000.00 | General |
| Category: DBS | ||||||
| 02/08/2022 | Merz Pharmaceuticals, LLC | — | Education | In-kind items and services | $79.56 | General |
| 12/18/2021 | Medtronic, Inc. | Percept (Device) | Travel and Lodging | In-kind items and services | $328.00 | General |
| Category: Deep Brain Neurostimulation | ||||||
| 12/18/2021 | Medtronic, Inc. | Percept (Device) | Travel and Lodging | In-kind items and services | $46.00 | General |
| Category: Deep Brain Neurostimulation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 253 | 541 | $123,164 | $33,301 |
| 2022 | 2 | 42 | 61 | $12,877 | $3,708 |
Total Patients
295
Total Services
602
Medicare Billing
$37,009
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 51 | 83 | $33,503 | $9,124 | 27.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 70 | $28,210 | $8,938 | 31.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 53 | 180 | $19,260 | $4,454 | 23.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $12,900 | $3,558 | 27.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 29 | 29 | $12,231 | $3,028 | 24.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 30 | 117 | $12,519 | $2,980 | 23.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 15 | $3,309 | $984.45 | 29.8% |
| 99421 | Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | Facility | 2023 | 16 | 22 | $1,232 | $234.96 | 19.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 21 | 25 | $9,025 | $2,743 | 30.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 21 | 36 | $3,852 | $965.55 | 25.1% |
About Ashley Paul
Ashley Paul is a Student in an Organized Health Care Education/Training Program healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/21/2016. The National Provider Identifier (NPI) number assigned to this provider is 1902250335.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ashley Paul has received a total of $33,507 in payments from pharmaceutical and medical device companies, with $390.70 received in 2024. These payments were reported across 49 transactions from 11 companies. The most common payment nature is "Grant" ($30,000).
As a Medicare-enrolled provider, Paul has provided services to 295 Medicare beneficiaries, totaling 602 services with total Medicare billing of $37,009. Data is available for 2 years (2022–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Neurology
- Location Baltimore, MD
- Active Since 04/21/2016
- Last Updated 05/18/2021
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1902250335
Products in Payments
- ACTIVA (Device) $20,000
- Vercise (Device) $10,000
- Percept (Device) $1,289
- NUPLAZID (Drug) $864.10
- INGREZZA (Drug) $419.30
- AUBAGIO (Drug) $166.52
- GOCOVRI (Drug) $124.72
- Ongentys (Drug) $110.52
- TYSABRI (Biological) $90.13
- Mavenclad (Biological) $86.19
- GILENYA (Drug) $63.69
- MS DISEASE STATE (Drug) $63.34
- BOTOX (Drug) $55.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Baltimore
George Gavrila, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $385,635
Student in an Organized Health Care Education/Training Program $385,635
Dr. Jason Akulian, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $379,132
Student in an Organized Health Care Education/Training Program $379,132
Gruschenka Mojica Sanchez, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $359,745
Student in an Organized Health Care Education/Training Program $359,745
Dr. John Rickard
Student in an Organized Health Care Education/Training Program — Payments: $162,277
Student in an Organized Health Care Education/Training Program $162,277
Sang Hun Lee
Student in an Organized Health Care Education/Training Program — Payments: $116,949
Student in an Organized Health Care Education/Training Program $116,949
Mariem Sawan, Mbbs, MBBS
Student in an Organized Health Care Education/Training Program — Payments: $83,712
Student in an Organized Health Care Education/Training Program $83,712